ENDRA Life Sciences Inc.
NDRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $275 | $234 | $224 |
| Gross Profit | $0 | -$275 | -$234 | -$224 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,190 | $5,004 | $6,554 | $5,483 |
| G&A Expenses | $7,056 | $0 | $0 | $0 |
| SG&A Expenses | $7,627 | $5,242 | $6,369 | $5,791 |
| Sales & Mktg Exp. | $571 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,817 | $10,245 | $12,923 | $11,274 |
| Operating Income | -$10,817 | -$10,521 | -$13,158 | -$11,498 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$691 | $460 | -$22 | $267 |
| Pre-Tax Income | -$11,508 | -$10,060 | -$13,179 | -$11,231 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,508 | -$10,060 | -$13,179 | -$11,231 |
| % Margin | – | – | – | – |
| EPS | -10.25 | -5.89 | -4.57 | -5.47 |
| % Growth | -74% | -28.9% | 16.5% | – |
| EPS Diluted | -10.25 | -5.89 | -6.84 | -5.47 |
| Weighted Avg Shares Out | 1,122 | 1,708 | 1,930 | 2,046 |
| Weighted Avg Shares Out Dil | 1,122 | 1,708 | 1,930 | 2,046 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $22 | $0 |
| Depreciation & Amortization | $46 | $275 | $234 | $224 |
| EBITDA | -$10,771 | -$9,785 | -$12,945 | -$11,007 |
| % Margin | – | – | – | – |